2021 – now: CSO & CMO POLYGON Therapeutics
2019 – now: Head Inserm U970 Team 5 “Immuno-metabolic mechanism of cardiovascular diseases”, Paris, France
2014 – now: Professor of Medicine, Division of Intensive Care Medicine, St-Antoine Hospital, Paris
2010 – 2014: Associate Professor of Medicine, Division of Intensive Care Medicine, St-Antoine Hospital
2010 – date: Scientific Reviewer for sereval peer-reviewed journals (J Clin Invest, J Exp Med, PNAS, Circulation, Nature Communications, Intensive Care Medicine, ATVB)
2012 – 2016: Member of the scientific commission of Inserm CSS4 « Physiologie et physiopathologie des systèmes cardiaque, vasculaire, pulmonaire, néphrologie et musculaire »
2014 – Date: Scientific Evaluation for several national and international organizations (British Heart Foundation, Austrian Heart Foundation, Netherlands Organization for Health Research and Development, Swiss National Foundation.)
2014 – Date: External evaluator of PhDs in several European countries (France, UK, Sweden, Germany, etc.)
Hafid Ait-Oufella is a clinician scientist who has made major contributions to cardiovascular immunology. He identified critical counter-regulatory immune mechanisms that tame the development and progression of cardiovascular disease such as regulatory T cells. He identified the crucial pathogenic role of B cells in the pathophysiology of atherosclerosis and deleterious post-ischemic cardiac remodeling. He revealed the key role of TREM-1 receptor in both human and experimental atherosclerotic cardiovascular dieases. Hafid Ait-Oufella also undertook innovative research into the pathophysiology of aortic aneurysms, opening new research avenues. He has made sustained and internationally recognized contributions to our understanding of cardiovascular immunology and atherosclerotic diseases and translated these novel findings into new therapeutic monoclonal antibodies approaches.